Thiazide and beta blocker
PreclinicalSmall molecule
Thiazide and beta blocker is one of 30 small molecule programs targeting Essential Hypertension. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
238 competitors in Essential Hypertension
#DrugCompanyPhaseTrials
1Edarbi
TakedaPhase 3
Benicar
NovartisPhase 3
Edarbi
TakedaPhase 3
Crestor
AstraZenecaPhase 3
Thalitone
Alnylam PharmaceuticalsPhase 3
Benicar
CCosette Pharmaceuticals, Inc.
Phase 3
Atacand
IIstituto Clinico Humanitas
Phase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zocor
OOrganon and Co
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thiazide and beta blocker. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Cambridge